InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.00%
)
US TECH 100
19,492.80
(
0.43%
)
Dow Jones
38,834.86
(
0.00%
)
Brent Oil
84.88
(
0.21%
)
Bitcoin
66,053.92
(
1.67%
)
Post# of 252256
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 119875
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 141661

Wednesday, 05/09/2012 4:48:39 PM

Wednesday, May 09, 2012 4:48:39 PM

Post# of 252256

Teva did not formally change any of its previous guidance and gave the excuse that the new CEO Levin needs more time and I guess he will lower the targets.

Agreed; however, after quantifying the effect from the new wholesaler agreements (#msg-75406710), I think 2012 US Copaxone sales will be closer to the upper bound than the lower bound of the $2.4-2.6B range mentioned in #msg-75390703. Do you agree?

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up